```json
{
"content": [
{
"type": "paragraph",
"content": "Cholestasis Pruritus Treatment segmentation by application reveals distinct therapeutic use cases. In-patient treatment dominates the market, accounting for approximately 60% of the segment, as severe cholestasis cases require hospital-based interventions such as intravenous therapies or monitoring. This segment is driven by acute care demands and regulatory mandates for institutionalized treatment. Conversely, out-patient treatment represents 40% of the market, focusing on chronic disease management through oral medications and follow-up therapies. This segment benefits from rising home healthcare adoption and patient-centric drug delivery models. The in-patient segment's larger share underscores the critical role of acute care settings in driving market revenue, while out-patient applications highlight the growing emphasis on long-term, cost-effective solutions."
},
{
"type": "paragraph",
"content": "Segmentation by Cholestasis Pruritus Treatment types highlights the evolving landscape of therapeutic modalities. Pharmaceutical therapies, including bile acid sequestrants (e.g., cholestyramine) and farnesoid X receptor agonists (e.g., obeticholic acid), constitute 70% of the market. These drugs address pruritus by modulating bile acid metabolism and are favored for their efficacy in primary biliary cholangitis. Non-pharmaceutical interventions account for 30%, encompassing phototherapy, dietary modifications, and supportive care. This segment grows steadily due to patient preference for non-drug alternatives, particularly in pediatric populations. The pharmaceutical segment drives innovation and revenue, whereas non-pharmaceutical approaches cater to niche patient needs and adjunctive care strategies. Together, they reflect a balanced market taxonomy driven by clinical guidelines and patient tolerance for treatment modalities."
}
],
"chartData": {
"segments": [
{ "name": "In-patient Treatment", "value": 60 },
{ "name": "Out-patient Treatment", "value": 40 }
]
}
}
```
